Literature DB >> 12142973

MR perfusion measurement of contrast uptaking lesions: consideration of T2* shortening due to interstitial contrast agent.

V Hietschold1, T Kittner, S Appold, N Abolmaali, M Laniado.   

Abstract

AIM: In MR perfusion measurements of contrast uptaking lesions, time intensity curves are hampered by T 1 shortening as well as by the change of T 2 * due to interstitial contrast material (CM). Using double echo sequences, the influence of T 1 can be mathematically eliminated. For correction of the T 2 * influence an empirical algorithm using time-intensity-curves exclusively measured in the suspected lesion is proposed.
METHODS: The interstitial CM concentration is assumed to be proportional to the change of the intensity for T E = 0 or to the change of the relaxation rate DeltaR 1 respectively. The intravascular CM concentration is estimated from DeltaR 2 *. It is adjusted to zero for a time point sufficiently late after the bolus injection by subtraction of the interstitial concentration. This method was applied to double echo FLASH measurements on 15 pharyngeal tumors.
RESULTS: The proposed correction transforms the time dependence of the estimated intravascular CM concentration into a plausible course.
CONCLUSION: Double echo perfusion measurements can be corrected for the interstitial CM induced T 2 * shortening without additional measurements with proneness to errors. This does not necessarily improve the diagnostic value, since possibly "implied multivariate aspects" of uncorrected parameters (here: contrast uptake of the lesion is related to tumor neoangiogenesis as well) are eliminated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142973     DOI: 10.1055/s-2002-32935

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  1 in total

1.  MR perfusion measurements on pharyngeal tumors: comparison of quantification strategies.

Authors:  Volker Hietschold; Thomas Kittner; Michele Schreyer; Steffen Appold; Bettina Beuthien-Baumann; Michael Laniado
Journal:  J Appl Clin Med Phys       Date:  2004-10-01       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.